Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Findings support SER-109 Phase 3 program as a potential new treatment option for C. difficile infection
“These additional SER-109 data provide valuable information about the
potential mechanism of action of microbiome therapeutics, an emerging
new field of medicine. Our results provide additional evidence
supporting the continued development of SER-109 in patients with
recurrent C. difficile infection. In addition, these new data
suggest that SER-109 may have important broader public health benefits
by reducing the spread of antibiotic resistance,” said
C. difficile infection is often treated with extended antibiotic regimens, resulting in damage to the natural gastrointestinal microbiome and proliferation of antibiotic resistant bacteria1. Data from Ford et al., based on analysis of SER-109 Phase 2 study samples, demonstrate that SER-109 administration increases microbiome diversity and that outgrowth of SER-109 bacteria is associated with a reduction in the abundance of antibiotic resistance genes in subjects’ gastrointestinal tract. These new results suggest that microbiome therapeutics have the potential to address the spread of antibiotic resistance, a major public health concern.
In a separate presentation, Henn et al. show that SER-109 administration and subsequent bacterial outgrowth leads to changes in the metabolic products created by the gastrointestinal microbiota, including higher concentrations of secondary bile acids. Secondary bile acids are generated by bacteria residing in the gut, and published studies suggest that these molecules inhibit the growth of C. difficile2. The findings provide important insights into the potential mechanism of action of SER-109 for C. difficile infection.
Oral Presentation Details:
Title: Treatment of Recurrent Clostridium difficile
Infection with SER-109 Reduces Gastrointestinal Carriage of
Antimicrobial Resistance Genes
Author: Ford C. et al.
Session:
Novel Therapies for Superbugs
Date: Friday,
Poster Presentation Details:
Title: Treatment of Recurrent Clostridium difficile
Infection with SER-109 Increases the Concentration of Secondary Bile
Acids in a Dose Dependent Manner
Author: Henn M. et al.
Session:
Microbiome and Beyond
Date: Thursday,
Symposium:
Title: An Ecological Approach to the
Treatment of Recurrent Clostridium difficile Infection: Picking
Up Where Antibiotics Leave Off
Speaker:
Date:
Location: Learning Lounge 2
About Seres Therapeutics
References
1. Wing W and Marina S, Microbial Biotechnology, 2017.
2.
Theriot CM et al., mSphere, 2016.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the ability of SER-109 to prevent the spread of antibiotic resistance, the ability of ECOSPOR III to support SER-109 approval, and the promise and potential impact of any of our microbiome therapeutics.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we are not currently
profitable and may never become profitable; our need for additional
funding; our limited operating history; our unproven approach to
therapeutic intervention; the lengthy, expensive, and uncertain process
of clinical drug development; protection of our proprietary technology
and the confidentiality of our trade secrets; potential lawsuits for, or
claims of, infringement of third-party intellectual property or
challenges to the ownership of our intellectual property; our patents
being found invalid or unenforceable; and our ability to retain key
personnel and to manage our growth. These and other important factors
discussed under the caption “Risk Factors” in our Quarterly Report on
Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005055/en/
Source:
IR and PR Contact:
Seres Therapeutics
Carlo Tanzi,
Ph.D., 617-203-3467
Vice President, Investor Relations and
Corporate Communications
ctanzi@serestherapeutics.com